Compare CDP & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDP | CDTX |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | N/A | 2015 |
| Metric | CDP | CDTX |
|---|---|---|
| Price | $29.49 | $220.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $33.29 | ★ $128.75 |
| AVG Volume (30 Days) | 934.6K | ★ 2.3M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | ★ 9.45 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $752,757,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | $22.09 | ★ N/A |
| Revenue Growth | ★ 0.43 | N/A |
| 52 Week Low | $23.92 | $15.22 |
| 52 Week High | $32.94 | $221.20 |
| Indicator | CDP | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 86.62 |
| Support Level | $28.57 | $219.60 |
| Resistance Level | $29.57 | $220.38 |
| Average True Range (ATR) | 0.56 | 0.74 |
| MACD | -0.14 | -3.92 |
| Stochastic Oscillator | 39.36 | 67.82 |
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.